CBD Oil for Reducing Emotional Impact of COVID-19
Key facts
- Who runs it
- University of Texas at Austin
- Where
- Austin, United StatesSee the site
- Trial code
- Status
- Suspended
- Phase
- Phase 2/3
- People taking part
- 200 people, planned
- Started
- 4 Dec 2020
- Ended
- 31 Dec 2023
- Type of study
- Interventional, 4 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- CBD Isolate
- Full Spectrum CBD Oil
- Broad-Spectrum CBD Oil
- Placebo Oil
- Record updated
- 22 November 2023
- Why it stopped
- Suspended (The UT IRB determined that CBD oil is being used as a drug as defined by the FDA. Therefore, an IND must be obtained for the use of CBD oil in this research study in accordance with FDA regulations, 21 CFR 312.)
Who can take part
- Age
- 18 years to 70 years
- Sex
- Women and men
- Healthy volunteers
- Can take part
The registry criteria, word for word
Show all 18 criteriaShow less
Who can take part
- Displays elevated symptom scores on one or more of the following established assessment instruments for depression (PROMIS-Depression), anxiety (PROMIS-Anxiety), Anger (PROMIS-Anger), sleep disturbance (PROMIS-Sleep); or Alcohol/Substance (PROMIS-Alcohol; PROMIS- Substance Use)
- Age between 18 to 70
- Fluent in English
- Has home access to the Internet
- Willingness to provide signed informed consent
- Willingness to refrain from all non-study CBD products during the 6-week study period
- Willing to complete a brief pre-study 7-day online symptom monitoring log
- Currently residing in the United States
Who cannot take part
- Currently taking seizure medications such as valproate, lamotrigine, or clobazam
- Currently taking thyroid medications such as levothyroxine
- Currently taking heart rhythm medications such as amiodarone
- Currently taking anti-hypertension medications
- History of a suicide attempt within the past 6 months
- Any medical problem that would preclude participating in the study including liver disease
- History of adverse reaction to CBD oil or other CBD products
- Allergic to coconut oil
- Current use of warfarin or other prescribed blood thinners,
- Pregnant or planning to become pregnant within the next 6 weeks
Where in United States
- University of Texas at Austin, Laboratory for the Study of Anxiety DisordersAustin, United States
About the trial
What the trial wants to find out
Our purpose is to conduct a 4-arm placebo-controlled clinical trial to investigate the relative clinical efficacy of 300 mg. of pure hemp-derived CBD isolate, 300 mg. of full spectrum CBD oil, 300 mg. of broad- spectrum CBD Oil, or Placebo oil among adults presenting with COVID-19 -induced stress reactions including one or more of the following: anxiety, depression, anger, substance use, or sleep disturbance.
The 4 groups in the trial
- CBD-Isolate 300 mg.Existing treatment, for comparison
Nightly oral administration of 300 mg. of CBD-Isolate for 28 consecutive days
Treatment: CBD Isolate
- Full-Spectrum CBD Oil 300 mg.Existing treatment, for comparison
Nightly oral administration of 300 mg. of Full Spectrum CBD Oil for 28 consecutive days
Treatment: Full Spectrum CBD Oil
- Broad-Spectrum CBD oil 300 mg.Existing treatment, for comparison
Nightly oral administration of 300 mg. of Broad-Spectrum CBD Oil for 28 consecutive days
Treatment: Broad-Spectrum CBD Oil
- Placebo OilPlacebo, for comparison
Nightly oral administration of 300 mg. of Placebo Oil for 28 consecutive days
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Use of CBD Oil for Reducing the Negative Emotional Impact of COVID-19: A Randomized Placebo-Controlled Clinical Trial
- Record updated
- 22 November 2023